Search
Isoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigational[L33204] Isoprenaline was granted FDA approval on 19 February 1948.[L33155] … Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-Isopropylnoradrenaline, N-IsopropylnorepinephrineGuanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnAn antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidineHuman C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigational[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]
Categories: Drugs Used in Hereditary AngioedemaLubiprostone
go.drugbank.com/drugs/DB01046ApprovedInvestigationalA prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. … Lubiprostone is a medication used in the management of idiopathic chronic constipation.
Categories: Prostaglandins EMipomersen
go.drugbank.com/drugs/DB05528ApprovedSpecifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. … Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.
Categories: Compounds used in a research, industrial, or household settingPolycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnIt is insoluble in water, dilute acids, and dilute alkali.
Categories: Compounds used in a research, industrial, or household settingChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnMedications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. … Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites.
Categories: Drugs Used in DiabetesSynonyms: N-(4-chlorophenylsulfonyl)-N'-propylurea, N-(p-chlorobenzenesulfonyl)-N'-propylureaAlclofenac
go.drugbank.com/drugs/DB13167ApprovedWithdrawnIt was withdrawn from the market in the United Kingdom in 1979.
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.